ID   TCC-S
AC   CVCL_W386
SY   TCCS; Tochigi Cancer Center-S
DR   Wikidata; Q54971863
RX   PubMed=11264164;
RX   PubMed=16130897;
CC   Population: Japanese.
CC   Doubling time: 27.96 +- 0.97 hours (PubMed=16130897); 25 +- 2 hours (PubMed=11264164).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=16130897).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   49Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 13
//
RX   PubMed=11264164; DOI=10.1182/blood.V97.7.1999;
RA   Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y.,
RA   Furukawa Y.;
RT   "In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in
RT   combination with commonly used antileukemic agents.";
RL   Blood 97:1999-2007(2001).
//
RX   PubMed=16130897; DOI=10.1111/j.1749-0774.2005.tb00054.x;
RA   Van P.N.T., Xinh P.T., Kano Y., Tokunaga K., Sato Y.;
RT   "Establishment and characterization of A novel Philadelphia-chromosome
RT   positive chronic myeloid leukemia cell line, TCC-S, expressing P210
RT   and P190 BCR/ABL transcripts but missing normal ABL gene.";
RL   Hum. Cell 18:25-33(2005).
//